Recently Published Projects

Published on June 16, 2021
Breast Reconstruction After Mastectomy
324 Studies • 6 Key Questions • 162 Extraction Forms
Project created on May 04, 2020
Last updated on October 06, 2021
Objectives: This systematic review will assess the surgical breast reconstruction options for women who are undergoing (or have undergone) mastectomy for breast cancer. Specifically, the review will address: (1) the (comparative) benefits and harms of IBR and AR (Key Question [KQ] 1) (2) the (comparative) benefits and harms of timing of IBR and AR in relation to chemotherapy and radiation therapy (KQ 2) (3) the (comparative) benefits and harms of various options for IBR (KQs 3, 4, and 5) (4) the (comparative) benefits and harms of various flap types for AR (KQ 6).
Published on May 28, 2021
A Descriptive Analysis of the Scientific Literature on Meteorological and Air Quality Factors and COVID-19
61 Studies • 9 Key Questions • 61 Extraction Forms
Project created on October 15, 2020
Last updated on August 06, 2021
Objectives: Descriptive systematic literature review from epidemiologic perspective of studies assessing influence of environmental and meteorological factors on COVID-19 transmission and severity.
Published on March 03, 2021
Catheter Ablation for Treatment of Atrial Fibrillation [Prospectively Entered]
50 Studies • 7 Key Questions • 50 Extraction Forms
Project created on March 03, 2021
Last updated on March 03, 2021
Objectives: Because catheter ablation is increasingly being used to treat AF patients in the Medicare population, and there is uncertainty regarding the efficacy and harms of this procedure in this population in particular, a systematic review to re-evaluate the current state of evidence, identify and evaluate inconsistencies in the evidence, and identify important research gaps is warranted to help inform clinical practice and policy.
Published on March 03, 2021
Behavioral programs for diabetes mellitus
166 Studies • 6 Key Questions • 166 Extraction Forms
Project created on March 03, 2021
Last updated on March 03, 2021
Objectives: A systematic review focusing on the effectiveness of behavioral programs for type 1 diabetes (T1DM), and identifying factors contributing to program effectiveness for type 2 diabetes (T2DM).
Published on March 03, 2021
First- and Second- Generation Antipsychotics for Children and Young Adults [Entered Retrospectively]
81 Studies • 4 Key Questions • 81 Extraction Forms
Project created on March 03, 2021
Last updated on March 03, 2021
Objectives: Methods: Two reviewers conducted study selection and quality assessment independently and resolved discrepancies by consensus. One reviewer extracted data, and a second reviewer verified the data. We conducted a descriptive analysis for all studies and performed metaanalyses when appropriate. Results: Eighty-one studies (64 trials and 17 cohort studies) examined the following conditions: pervasive developmental disorders (12 studies); attention deficit hyperactivity disorder (ADHD) or disruptive behavior disorders (8 studies); bipolar disorder (11 studies); schizophrenia and related psychosis (31 studies); Tourette syndrome (7 studies); behavioral issues (4 studies); and multiple conditions (9 studies). One study reported data on both bipolar disorder and schizophrenia. The majority of the trials had a high risk of bias. The methodological quality of the cohort studies was moderate. Results are presented by outcome below: Symptoms: The strength of evidence for all head-to-head comparisons of FGAs and SGAs was low or insufficient to draw conclusions. SGAs were favored over placebo for behavior symptoms (ADHD and disruptive behavior disorders), the Clinical Global Impressions scale (ADHD and disruptive behavior disorders, bipolar disorder, and schizophrenia), positive and negative symptoms (schizophrenia), and tics (Tourette syndrome) (moderate strength of evidence). Other short- and long-term outcomes: All head-to-head comparisons had low or insufficient strength of evidence. There was no significant difference between SGAs and placebo for suicide related behaviors (moderate strength of evidence). The evidence was rated as insufficient to draw conclusions for health-related quality of life, involvement with the legal system, and other patient-, parent-, or care provider-reported outcomes for all conditions. Adverse events: All outcomes comparing FGAs with SGAs had low or insufficient strength of evidence. Outcomes comparing FGAs versus FGAs and FGAs versus placebo had insufficient evidence. Risperidone was favored over olanzapine for dyslipidemia; olanzapine was favored over risperidone for prolactin-related events; and both quetiapine and risperidone were favored over olanzapine for weight gain (moderate strength of evidence). For nearly all outcomes and comparisons, placebo resulted in significantly fewer adverse events than SGAs. Subpopulations: Thirty-six studies examined the association between various patient subpopulations and outcomes. Most concluded that the results did not differ by subpopulations, or findings were discordant across studies. Conclusion: Evidence comparing FGAs with SGAs, various FGAs, and FGAs with placebo was very limited. Some SGAs appear to have a better side-effect profile than other SGAs. Compared with placebo, SGAs have better symptom improvement but more adverse events. Future high quality research examining head-to-head antipsychotic comparisons is needed.